Loading…
Restoring Safeguards for Dangerous Abortion Drugs Act
Legislative Progress
Introduced
September 30, 2025
Latest Action
September 30, 2025
Primary Sponsor
Mary E. MillerRepublican(IL)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2026 · second_quarter · Pharmacy
Shield Laws Chemical abortion drugs S. 1631, H. R. 5646 - Restoring Safeguards for Dangerous Abortion Drugs Act H.R. 679 - To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes H.R. 795 - Pregnancy Is Not an Illness Act H.R. 627 - Ensuring Accurate & Complete Abortion Data Reporting Act H.R. 6466 - Forced Abortion Prevention and Accountability Act Presidential administrative actions S.4066 - Safeguarding Women from Chemical Abortion Act S.3697, H.R.685 - SAVE Moms and Babies Act of 2026 H.R.5485 - Second Chance at Life Act H.R. 9421 - Ban Abortion By Mail Act H.R. 729 - Teleabortion Prevention Act of 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $420,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Family issues/Abortion/Adoption
Advocacy against Pregnant and Parenting Women and Families Act (H.R.6945) (House) Advocacy against Pregnant Students Rights Act (H.R. 6359, S. 3627) (House and Senate) Advocacy for Protecting Health Care and Lowering Costs Act (S. 2556, H.R. 4849) (House and Senate) Advocacy for Momnibus Act (H.R. 7973) (House) Advocacy against Restoring Safeguards for Dangerous Abortion Drugs Act (H.R. 5646, S. 1631) (House and Senate) Advocacy against Pregnant Students' Rights Act (H.R.6359, S.3627) (House and Senate) Advocacy for veterans' abortion access (HJ Res 144, SJ Res 103) (House and Senate) Advocacy for WIC benefits for post-partum parents, as part of the Extending WIC for New Moms Act (S.4191) (Senate) Advocacy for veterans' contraception access in Equal Access to Contraception for Veterans Act (H.R.211) (House) Advocacy for military abortion access - MARCH Act (H.R.3969) (House and Senate) Advocacy for Abortion Provider Appreciation Day resolution (S.Con.Res.28/H.Con.Res.78) (House and Senate) Advocacy for Right to IVF Act (Senate) (no bill # available) Advocacy for Let Doctors Provide Reproductive Health Care Act (no bill # available) (Senate) Advocacy against appropriations for anti-abortion centers (no bill # available) (House and Senate) Advocacy for robust abortion rights bill (no bill # available) (House and Senate) Advocacy for a bill protecting federal workers who are stationed in anti-abortion states (no bill # available) (House) Advocacy against anti-abortion policies in FY27 appropriations bills including the Hyde and Weldon Amendments and funding for anti-abortion centers (no bill # available) (House and Senate) Advocacy for reproductive health care access amendments in the FY27 NDAA (no bill # available) (House and Senate)
Client expense: $85,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Pharmacy
Shield Laws Chemical abortion drugs S. 1631, H. R. 5646 - Restoring Safeguards for Dangerous Abortion Drugs Act H.R. 679 - To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes H.R. 795 - Pregnancy Is Not an Illness Act H.R. 627 - Ensuring Accurate & Complete Abortion Data Reporting Act H.R. 6466 - Forced Abortion Prevention and Accountability Act Presidential administrative actions S.4066 - Safeguarding Women from Chemical Abortion Act
Client expense: $380,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Family issues/Abortion/Adoption
Shield laws Chemical abortion drugs H.R. 7, S. 186 No Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act of 2025; S. 2955; HR 6466 -Forced Abortion Prevention and Accountability Act; Patient Protection and Affordable Care Act; Abortion funding; IVF issues; National Defense Authorization Act; S. 1631, H. R. 5646 Restoring Safeguards for Dangerous Abortion Drugs Act; H.R. 629 Ending Chemical Abortions Act; H.R. 679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes; H.R. 795 Pregnancy Is Not an Illness Act; H.R. 627 Ensuring Accurate & Complete Abortion Data Reporting Act; H.R. 6466 Forced Abortion Prevention and Accountability Act; Presidential Administration Actions; S.3264, H.R.6538 More Affordable Care Act; H.R.6359 Pregnant Students Rights Act; H.R.4876 - Reproductive Freedom for Veterans Act H.R.7681 - HSAs For All Act H.R.8084 - Access to LARCs Act H.R.8083 -Allowing Greater Access to Safe and Effective Contraception Act S.4066 - Safeguarding Women from Chemical Abortion Act H.R. 7286 - To amend the Internal Revenue Code of 1986 to revoke the tax-exempt status of organizations that provide, or provide funding for, abortion. H.R.7286 - Chemical Abortion Risk Awareness Act H.R.7235- Protecting Motherhood Act S.3999 - Women Veterans Specialty Care Access Act H.R.7148 - Consolidated Appropriations Act, 2026 H.R.6938 - Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriation Act, 2026 H.R.7983 - Clean Water for All Life Act
Client expense: $380,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2025 · fourth_quarter · Family issues/Abortion/Adoption
H.R. 1 One Big Beautiful Bill Act; H.R.2557 IVF For Military Families Act; S.2035 Protect IVF Act; H.R.6797 To amend title 10, United States Code, to provide fertility treatment under the TRICARE; Shield laws, chemical abortion drugs, H.R. 7, S. 186 No Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act of 2025; Dismemberment Abortion Ban Act; H.R. 5485 Second Chance at Life Act of 2025; H.R. 6501, Fitzpatrick Discharge Petition #12 Bipartisan Health Insurance Affordability Act; H.R. 6575, Gottheimer Petition #13 Common Ground for Affordable Health Care Act; H.R. 1834, Jeffries Discharge Petition #10 Breaking the Gridlock Act; S.2955 , H.R.6466 Forced Abortion Prevention and Accountability Act; Patient Protection and Affordable Care Act; Abortion funding; S. 2882 Continuing Appropriations and Extensions and Other Matters Act; S.3385 Lower Health Care Costs Act; H.R.5371 Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act; Contraception issues; IVF issues; National Defense Authorization Act; Supreme Court Decisions; S. 1631, H. R. 5646 Restoring Safeguards for Dangerous Abortion Drugs Act; H.R. 629 Ending Chemical Abortions Act; H.R. 679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes; H.R. 795 Pregnancy Is Not an Illness Act; H.R. 796 Second Chance for Moms Act; H.R. 1349 Womens Protection in Telehealth Act; H.R. 1525 Protecting Life from Chemical Abortions Act; H.R. 627 Ensuring Accurate & Complete Abortion Data Reporting Act; H.R. 6466 Forced Abortion Prevention and Accountability Act; H.R. 729 Teleabortion Prevention Act of 2025; S.3389 Lowering Health Care Costs for Americans Act; Presidential Administration Actions; S.3011 Prohibiting Abortion & Transgender Procedures on the Exchanges Act; S.3264, H.R.6538 More Affordable Care Act; H.R. 6703 Lower Health Care Premiums for All Americans Act; S.3391 Accountability for Better Care Act of 2025; S. 3386 Health Care Freedom for Patients Act of 2025; H.R.6512 To Empower American Families with Direct Control Over Healthcare Dollars, Codify President Trump's Proven Reforms for Flexibility and Choice, Prohibit Taxpayer Funding for Abortion and Gender Transition Procedures, Eliminate Waste and Fraud in the Affordable Care Act, and Reject Extensions of Enhanced Subsidies to Insurance Companies; H.R.1157 Affordable Care and Comprehensive Economic Support through Savings (ACCESS) Act; H.R.2589 Consensual Donation and Research Integrity Act of 2025; H.R.5969 LABEL Act; H.Res.803 Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes; H.R. 6372 D.C. Shield Law Repeal Act; H.R.6359 Pregnant Students Rights Act; H.R. 6191 No Taxpayer Funded Abortion Travel for Illegal Aliens Act
Client expense: $420,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2025 · fourth_quarter · Pharmacy
Shield Laws; Chemical abortion drugs; H.R. 5485 Second Chance at Life Act of 2025; Supreme Court Decisions; S. 1631, H. R. 5646 Restoring Safeguards for Dangerous Abortion Drugs Act; H.R. 629 Ending Chemical Abortions Act; H.R. 679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes; H.R. 795 Pregnancy Is Not an Illness Act; H.R. 796 Second Chance for Moms Act; H.R. 1349 Womens Protection in Telehealth Act; H.R. 1525 Protecting Life from Chemical Abortions Act; H.R. 627 Ensuring Accurate & Complete Abortion Data Reporting Act; H.R. 6466 Forced Abortion Prevention and Accountability Act; H.R. 729 Teleabortion Prevention Act of 2025; Presidential Administration Actions; H.R.5969 LABEL Act
Client expense: $420,000 · Firm income: Not reported
2025 · third_quarter · Family issues/Abortion/Adoption
H.R. 1 One Big Beautiful Bill Act; H.R.2557 IVF For Military Families Act; S.2035 Protect IVF Act; S.1882, H.R.3589 RESTORE Act; Shield laws; Chemical abortion drugs; H.R. 7, S. 186 No Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act of 2025; Dismemberment Abortion Ban Act; H.R. 4964 Child Interstate Abortion Notification Act; H.R. 5485 Second Chance at Life Act of 2025; S.2418 HEALING Mothers and Fathers Act; S.2433 Neonatal Care Transparency Act of 2025; H.Res.611 Expressing the importance of accurate information for medical professionals treating pregnant women and their unborn children in the emergency department, and for informing the general public, and for other purposes; S.2955 A bill to amend title 18, United States Code, to establish Federal penalties for the knowing and intentional administration of any abortion-inducing drug to a woman without her informed consent, if the abortion-inducing drug has been shipped or transported in interstate commerce, and for other purposes; Patient Protection and Affordable Care Act; Abortion funding; S. 2882 Continuing Appropriations and Extensions and Other Matters Act, 2026; S. 5371 Continuing Appropriations and Extensions Act, 2026; Contraception issues; IVF issues; National Defense Authorization Act; Supreme Court Decisions; H.R.679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes; S. 1631, H. R. 5646 Restoring Safeguards for Dangerous Abortion Drugs Act; Administration Personnel and Judicial Nominees; Presidential Administration Actions
Client expense: $360,000 · Firm income: Not reported
| Republican |
| MS |
| Pat Harrigan | Republican | NC |
| Randy K. Weber, Sr. | Republican | TX |
| Sheri Biggs | Republican | SC |
| Tim Burchett | Republican | TN |
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office